CoChat
Sign Up
Cited by 301Fatty Acid Research and HealthAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Resolution of inflammation is altered in Alzheimer's disease

Open access
Wang, Xiuzhe, Zhu, Mingqin, Hjorth, Erik, Cortés‐Toro, Veronica, Eyjolfsdottir, Helga, Graff, Caroline, Nennesmo, Inger, Palmblad, Jan +6 more·2015·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2013.12.024PMC PMC4275415
Open this paper in CoChat — free account

Abstract

Background: Resolution is the final stage of the inflammatory response, when restoration of tissue occurs. Failure may lead to chronic inflammation, which is known as part of the pathology in the brain of individuals with Alzheimer's disease (AD). Methods: Specialized pro‐resolving mediators (SPMs), receptors, biosynthetic enzyme, and downstream effectors involved in resolution were analyzed in postmortem hippocampal tissue from AD patients and non‐AD subjects. SPMs were analyzed in cerebrospinal fluid (CSF). Results: SPMs and SPM receptors were detected in the human brain. Levels of the SPM lipoxin A 4 (LXA 4 ) were reduced in AD, both in the CSF and hippocampus. An enzyme involved in LXA 4 synthesis and two SPM receptors were elevated in AD brains. LXA 4 and RvD1 levels in CSF correlated with Mini‐Mental State Examination (MMSE) scores. Conclusions: A resolution pathway exists in the brain and the alterations described herein strongly suggest a dysfunction of this pathway in AD. MMSE correlations suggest a connection with cognitive function in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.12.024

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Analysis of postmortem hippocampal tissue from AD patients found an association between reduction of SPMs and cognitive decline.

    “Analysis of postmortem hippocampal tissue from AD patients also found the association between reduction of SPMs and cognitive decline.425”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [425]

    Results §3.2.1 reports lower levels of the SPM LXA4 in postmortem hippocampal tissue from AD patients than from controls. The association with MMSE scores, however, was found for SPM levels in CSF across SCI, MCI, and AD patients (Results §3.1), not for levels measured in hippocampal tissue. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

  • Numerous studies have identified abnormality of inflammation resolution in AD, including abnormality in the profile of SPMs and its receptors.

    “Numerous studies have identified abnormality of inflammation resolution in AD, including the abnormality in the profile of SPMs and its receptors.175,425,426”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [425]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. [1]Castellani RJ Rolston RK Smith MA Alzheimer disease Dis Mon 2010 56 484 546 20831921 PMC2941917
  2. [2]Cagnin A Brooks DJ Kennedy AM Gunn RN Myers RD Turkheimer FE In vivo measurement of activated microglia in dementia Lancet 2001 358 461 467 11513911
  3. [3]Griffin WS Stanley LC Ling C White L MacLeod V Perrot LJ Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease Proc Natl Acad Sci U S A 1989 86 7611 7615 2529544 PMC298116
  4. [4]Swardfager W Lanctot K Rothenburg L Wong A Cappell J Herrmann N A meta-analysis of cytokines in Alzheimer's disease Biol Psychiatry 2010 68 930 941 20692646
  5. [5]Carpenter AF Carpenter PW Markesbery WR Morphometric analysis of microglia in Alzheimer's disease J Neuropathol Exp Neurol 1993 52 601 608 8229079
  6. [6]Combs CK Karlo JC Kao SC Landreth GE β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis J Neurosci 2001 21 1179 1188 11160388 PMC6762255
  7. [7]McGeer PL McGeer EG NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies Neurobiology of Aging 2007 28 639 647 16697488
  8. [10]Serhan CN Hamberg M Samuelsson B Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes Proc Natl Acad Sci U S A 1984 81 5335 5339 6089195 PMC391698
  9. [11]Serhan CN Lipoxin biosynthesis and its impact in inflammatory and vascular events Biochim Biophys Acta 1994 1212 1 25 8155718
  10. [12]Maddox JF Serhan CN Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction J Exp Med 1996 183 137 146 8551217 PMC2192402
  11. [13]Takano T Fiore S Maddox JF Brady HR Petasis NA Serhan CN Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors J Exp Med 1997 185 1693 1704 9151906 PMC2196289
  12. [15]Fiore S Maddox JF Perez HD Serhan CN Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor J Exp Med 1994 180 253 260 8006586 PMC2191537
  13. [16]Maderna P Cottell DC Toivonen T Dufton N Dalli J Perretti M FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis FASEB J 2010 24 4240 4249 20570963 PMC4338542
  14. [18]Krishnamoorthy S Recchiuti A Chiang N Yacoubian S Lee CH Yang R Resolvin D1 binds human phagocytes with evidence for proresolving receptors Proc Natl Acad Sci U S A 2010 107 1660 1665 20080636 PMC2824371
  15. [19]Arita M Bianchini F Aliberti J Sher A Chiang N Hong S Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 J Exp Med 2005 201 713 722 15753205 PMC2212834
  16. [20]Serhan CN Krishnamoorthy S Recchiuti A Chiang N Novel anti-inflammatory - pro-resolving mediators and their receptors Curr Top Med Chem 2011 11 629 647 21261595 PMC3094721
  17. [21]Lukiw WJ Cui JG Marcheselli VL Bodker M Botkjaer A Gotlinger K A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease J Clin Invest 2005 115 2774 2783 16151530 PMC1199531
  18. [22]Sobrado M Pereira MP Ballesteros I Hurtado O Fernandez-Lopez D Pradillo JM Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPAR-γ-dependent, neuroprotective effects of rosiglitazone in experimental stroke J Neurosci 2009 29 3875 3884 19321784 PMC6665034
  19. [23]Wu Y Zhai H Wang Y Li L Wu J Wang F Aspirin-triggered lipoxin A(4) attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase Neurochem Res 2012 37 1690 1696 22552474
  20. [24]Decker Y McBean G Godson C Lipoxin A4 inhibits IL-1β-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells Am J Physiol Cell Physiol 2009 296 C1420 C1427 19357230
  21. [25]Medeiros R Kitazawa M Passos GF Baglietto-Vargas D Cheng D Cribbs DH Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice Am J Pathol 2013 182 1780 1789 23506847 PMC3644736
  22. [26]Xu ZZ Zhang L Liu T Park JY Berta T Yang R Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions Nature Medicine 2010 16 592 597 1p following 7. PMC2866054 20383154
  23. [28]Winblad B Palmer K Kivipelto M Jelic V Fratiglioni L Wahlund LO Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment J Internal Med 2004 256 240 246 15324367
  24. [30]Dalli J Serhan CN Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators Blood 2012 120 e60 e72 22904297 PMC3471524
  25. [31]Sarlus H Höglund CO Karshikoff B Wang X Lekander M Schultzberg M Allergy influences the inflammatory status of the brain and enhances tauphosphorylation J Cell Mol Med 2012 16 2401 2412 22356650 PMC3823434
  26. [33]Thal DR Holzer M Rub U Waldmann G Gunzel S Zedlick D Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia Exp Neurol 2000 163 98 110 10785448
  27. [34]Mercken M Vandermeeren M Lubke U Six J Boons J Van de Voorde A Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes Acta Neuropathol 1992 84 265 272 1384266
  28. [35]Zhao Y Calon F Julien C Winkler JW Petasis NA Lukiw WJ Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR-γ-mediated mechanisms in Alzheimer's disease models PLoS ONE 2011 6 e15816 21246057 PMC3016440
  29. [36]Brash AR Boeglin WE Chang MS Discovery of a second 15S-lipoxygenase in humans Proc Natl Acad Sci U S A 1997 94 6148 6152 9177185 PMC21017
  30. [37]Waechter V Schmid M Herova M Weber A Gunther V Marti-Jaun J Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages J Immunol 2012 188 1856 1867 22246625
  31. [38]Le Y Gong W Tiffany HL Tumanov A Nedospasov S Shen W Amyloid β42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1 J Neurosci 2001 21 RC123 11160457 PMC6763825
  32. [39]Kitamura Y Shimohama S Koike H Kakimura J-I Matsuoka Y Nomura Y Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-γ in Alzheimer's disease brains Biochem & Biophys Res Commun 1999 254 582 586 9920782
  33. [40]Remarque EJ Bollen EL Weverling-Rijnsburger AW Laterveer JC Blauw GJ Westendorp RG Patients with Alzheimer's disease display a pro-inflammatory phenotype Exp Gerontol 2001 36 171 176 11162920
  34. [41]Bagnoli S Cellini E Tedde A Nacmias B Piacentini S Bessi V Association of IL10 promoter polymorphism in Italian Alzheimer's disease Neurosci Lett 2007 418 262 265 17420099
  35. [42]Souza DG Fagundes CT Amaral FA Cisalpino D Sousa LP Vieira AT The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice J Immunol 2007 179 8533 8543 18056401
  36. [43]Spera PA Ellison JA Feuerstein GZ Barone FC IL-10 reduces rat brain injury following focal stroke Neurosci Lett 1998 251 189 192 9726375
  37. [44]Ikonomovic MD Abrahamson EE Uz T Manev H Dekosky ST Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease J Histochem Cytochem 2008 56 1065 1073 18678882 PMC2583907
  38. [45]Pratico D Zhukareva V Yao Y Uryu K Funk CD Lawson JA 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress Am J Pathol 2004 164 1655 1662 15111312 PMC1615676
  39. [46]Higgs GA Bax CM Moncada S Inflammatory properties of lipoxygenase products and the effects of indomethacin and BW755C on prostaglandin production, leukocyte migration, and plasma exudation in rabbit skin Adv Prostaglandin Thromboxane Leukot Res 1982 9 331 339 6211959
  40. [49]Hansson O Zetterberg H Buchhave P Londos E Blennow K Minthon L Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 2006 5 228 234 16488378

Cited by

Sorted by citations

Authors
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., Fitzgerald, J. M., Serhan, C. N., Granholm, A., & Schultzberg, M.
Affiliations
  • Karolinska Institutet (SE)
  • Department of Neurobiology, Care Sciences and Society, Section of Neurodegeneration Karolinska Institutet Stockholm Sweden
  • Medical University of South Carolina (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Schultzberg, Marianne
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-02-14
Volume
11
Issue
1
Pages
40
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2013.12.024
PMC
PMC4275415
OpenAlex
W2166487622
Cited by
301
References
8
Citations by year
2026: 12 · 2025: 22 · 2024: 28 · 2023: 15 · 2022: 29 · 2021: 41 · 2020: 32 · 2019: 26 · 2018: 30 · 2017: 28 · 2016: 10 · 2015: 14 · 2014: 13
FWCI
20.18
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Vetenskapsrådet (072194)
  • Swedish Brain Power
  • Knut och Alice Wallenbergs Stiftelse
  • Karolinska Institutet
  • Stiftelsen för Gamla Tjänarinnor
  • Gun och Bertil Stohnes Stiftelse
  • Petrus och Augusta Hedlunds Stiftelse
  • National Institutes of Health (P01GM095467, GM038765)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, inflammation resolution
MeSH terms
Aged, Alzheimer Disease, Docosahexaenoic Acids, Female, Hippocampus, Humans, Inflammation, Lipoxygenase, Male, Middle Aged, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Inflammation Mediators, Receptors, Formyl Peptide, Lipoxins, Receptors, Lipoxin, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review